Performance of my book "Best stocks to buy for 2021 2nd Edition
Both my book "Best stocks to buy for 2021 2nd Edition" and this book "100 Best stocks to buy in 2020" received 4.5 rating.
The
biggest difference is this book and the previous book both did not beat
S&P 500, the market to most, and my last two books beat S&P 500
by a good margin.
They sold over 250,000 copies and my books in the series sold a small fraction of that amount. It must be marketing.
The following is the detail of my performances.
Management Summary
Book
|
Beat SPY by
(see Methodology)
|
Best Book
for 2021 2nd Edition
|
404%
|
Best Book
for 2021
|
83%
|
Best Book
to Buy from August, 2020”.
|
29%
|
This new
edition of “Best Book for 2021 2nd Edition” (i.e. this book) has a
new list of recommended stocks. The performance is from the publish date to
3/1/2021.
SPY is an
ETF simulating the S&P500 index.
Performance of the first edition of my book “Best Stocks
for 2021”
Besides the
primary list of recommended stocks, we have several lists.
The date range is from 12/10/2020
(the publish date) to today, 02/06/2021 (almost two months later). It is close
to the publish date of this edition. See Methodology for details.
List (#of stocks)
|
Return
|
Annualized
|
Beat SPY1
|
Primary
list (4)
|
10%
|
67%
|
83%
|
Primary
list without GLD (3)3
|
14%
|
92%
|
152%
|
Secondary
list (6)
|
29%
|
185%
|
406%2
|
Year-End
list (5 )
|
8%
|
49%
|
34%
|
Secondary
list for Year-End (5)
|
10%
|
65%
|
78%
|
Secondary
list without foreign countries (2)
|
34%
|
215%
|
486%2
|
1 “Beat SPY by” = (Return – SPY Return) / SPY
Return. Again, dividends & fees are not considered.
2 Not a typo.
3 Gold
is optional and it is used for safety.
SPY, an
ETF simulating S&P500 index, is used as a yardstick. The numbers below have
been rounded up for easier to read. Interestingly, the secondary lists
performed better. All lists have positive returns and beat SPY by good margins.
It seems this time the research work with the current market conditions; it may
not in future conditions. I am not responsible for any errors; I did double
check the figures.
Why this edition of this book
The
original book is about 2 months old, and now we have a new edition. I include a
new list of recommended stocks in this edition plus a bonus list for short-term
buy. Buy this book as a subscription service as I expect a lot of repeated buyers;
if it continues to work, the price of this book is trivial.
The
primary reason of the short duration from the initial publish date is the incredible performances of the
recommended stocks. All the lists of the recommended stocks beat SPY (an ETF
simulating the market) by good margins. The performances are REAL based on my
book. A similar book does not even stated their previous performance as it did
not beat the market for at least the last two years in a row. Some said their
recommended stocks appreciate many times, but they did not say how many of the
recommended stocks losing most of their values.
Important
notice. Past performance have nothing to do with future performances. Consult your financial advisor before
taking any action.
Performance of my last book “Best Stocks to
buy from August, 2020”
The performance is the returns
from 07/28/2020 to 12/07/2020. The average of the 14 recommended stocks beats
SPY (an ETF simulating S&P500 stocks) by 29%. The 29% is unbelievable as
SPY has been weighted heavily by a lot of tech stocks such as Apple, Tesla and
Microsoft, and they have been increased in value substantially during this
period. If you believe they will continue this trend, SPY or any ETF weighted
on tech stocks would be beneficial. However, I believe they are peaking and the
fall seems inevitable – it is my personal opinion.
There are 13 winners and 1 loser.
Again, dividends and fees have not been included. CMCSA and FDX are big winners profiting from
the pandemic.
Symbol
|
Name
|
Sector
|
True EY
|
Return
|
Ann. Return
|
ABBV
|
AbbVie
|
Drug
|
7%
|
10%
|
27%
|
ABT
|
Abbott
|
Drug
|
3%
|
8%
|
21%
|
CHE
|
Chemed
|
Diversified
|
4%
|
4%
|
12%
|
CMCSA
|
Comcast
|
Media
|
11%
|
19%
|
52%
|
FDX
|
FedEx
|
Transport
|
8%
|
76%
|
211%
|
GTS
|
Triple-S
|
Health
|
N/A
|
26%
|
72%
|
JNJ
|
Jonson
& J
|
Drug
|
6%
|
2%
|
4%
|
MCK
|
McKesson
|
Drug
|
8%
|
16%
|
45%
|
MSFT
|
Microsoft
|
Software
|
4%
|
6%
|
18%
|
SCHN
|
Schnitzer
|
Metal
|
10%
|
46%
|
127%
|
SMCI
|
Super
Micro
|
Computer
|
11%
|
9%
|
24%
|
UFPI
|
Universal
|
Building
|
10%
|
-6%
|
-17%
|
UNH
|
United
Health
|
Health
|
9%
|
15%
|
43%
|
ZBRA
|
Zebra
Tech
|
Computer
|
5%
|
39%
|
107%
|
|
|
|
|
|
|
Avg.
|
|
|
|
19%
|
53%
|
|
|
|
SPY
|
15%
|
41%
|
|
Beat SPY by
|
|
|
|
29%
|
Methodology
·
‘Beat SPY by “= (Return – SPY’s return) / (SPY’s
return) with adjustments to negative numbers.
·
Dividends and fees are not included. Hence, the
ratio usually looks better than it actually is.
·
Past performances have nothing to do with future
performances.
So far, the last
two books perform well with the market conditions.
The performances
are for reference only. These incredible performances are not sustainable.
·
Start date and end date could be one or two days
off. I need to prepare performance calculations at least one day before the
publish date, so I can enter the updated info for the recommended stocks.
·
Start date usually is the publish date;
sometimes it is one day off.
·
End date usually is within a few days of the
publish date of the next book in the series. However, if available, it could be
one year after the publish date of the last book, or today’s date for long-term
recommendation (usually the primary list). It could be one, two or up to 3
months for the short-term lists (year-end losers, momentum and short stocks).
·
True EY is the earnings yield considering debts
and cash. Compare it to one-year Treasuries and CD which are basically risk
free. It is the reciprocal of “EV/EBITDA”.
It is obtained from Yahoo!Finance (under Statistics).
·
Most figures are rounded up for easy reading,
but not in the calculation in “Beat SPY by”.
·
In the future edition, I may add the
performances of older books in this series.
I should have
sold a lot of books in this series, if readers buy this kind of book based on
past performances. I have not so far. Recommend
this book to your friends if you want this series to be continued and/or at
this low price. Again, you should consult
your financial advisor before taking any actions. I am not liable for any
of your trades. For my stock recommendations before the next book, you can be
my Patreon and search for Tony Pow. https://www.patreon.com